Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance.

Wang, Hongwei

Imatinib mesylate (STI-571) enhances antigen-presenting cell function and overcomes tumor-induced CD4+ T-cell tolerance. [electronic resource] - Blood Feb 2005 - 1135-43 p. digital

Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.

0006-4971

10.1182/blood-2004-01-0027 doi


Amino Acid Sequence
Animals
Antigen-Presenting Cells--immunology
Antineoplastic Agents--pharmacology
Benzamides
Bone Marrow Cells--immunology
CD4-Positive T-Lymphocytes--immunology
Dendritic Cells--drug effects
Imatinib Mesylate
Immune Tolerance--drug effects
Lymphoma--immunology
Macrophages--drug effects
Mice
Mice, Inbred BALB C
Molecular Sequence Data
Neoplasms--drug therapy
Ovalbumin--chemistry
Peptide Fragments--chemistry
Piperazines--pharmacology
Pyrimidines--pharmacology